Australia markets closed

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
23.73+0.78 (+3.40%)
As of 12:53PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close22.95
Open23.15
Bid23.62 x 900
Ask23.70 x 1200
Day's range22.50 - 23.73
52-week range16.49 - 32.36
Volume256,944
Avg. volume708,080
Market cap1.447B
Beta (5Y monthly)0.70
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Xencor to Present at Upcoming Investor Conferences

    PASADENA, Calif., February 28, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences:

  • Business Wire

    Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

    PASADENA, Calif., February 27, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a review of recent business and clinical highlights. The Company also presented encouraging early clinical data from its Phase 2 study of vudalimab monotherapy for patients with clinically defined

  • Business Wire

    Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

    PASADENA, Calif., February 20, 2024--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report financial results for the fourth quarter and full year 2023 after the market closes on Tuesday, February 27, 2024.